Finding the ‘Guilty’ Gene Variant of Sporadic Parkinson’s Disease Via CRISPR/Cas9

被引:0
|
作者
Shenzhao Lu
Jiawei Zhou
机构
[1] Chinese Academy of Sciences,Institute of Neuroscience, State Key Laboratory of Neuroscience, Shanghai Institutes for Biological Sciences
来源
Neuroscience Bulletin | 2017年 / 33卷
关键词
Parkinson’s disease; Genetic variant; CRISPR/Cas9;
D O I
暂无
中图分类号
学科分类号
摘要
Parkinson’s disease (PD) is a common neurodegenerative disorder affecting millions of people worldwide, but its cause and pathogenesis are still not fully understood. Earlier studies have shown that SNCA, which encodes α-synuclein, is one of the key genes associated with PD. Single-nucleotide polymorphism (SNP) variants of SNCA are thought to be correlated with disease onset. The underlying mechanisms however are enigmatic. A recent study published in Nature revealed that one of the SNP variants in the SNCA non-coding element elevated α-synuclein expression in human neurons by reducing the binding efficiency of transcription factors, demonstrating a previously uncharted role for SNPs in the pathogenesis of PD.
引用
收藏
页码:115 / 117
页数:2
相关论文
共 50 条
  • [21] NHEJ and CRISPR–Cas9 improve gene therapy
    Eytan Zlotorynski
    Nature Reviews Molecular Cell Biology, 2017, 18 (1) : 4 - 4
  • [22] CRISPR/Cas9 Essential Gene Editing in Drosophila
    Osadchiy, I. S.
    Kamalyan, S. O.
    Tumashova, K. Y.
    Georgiev, P. G.
    Maksimenko, O. G.
    ACTA NATURAE, 2023, 15 (02): : 70 - 74
  • [23] Optical Control of CRISPR/Cas9 Gene Editing
    Hemphill, James
    Borchardt, Erin K.
    Brown, Kalyn
    Asokan, Aravind
    Deiters, Alexander
    JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2015, 137 (17) : 5642 - 5645
  • [24] Spatiotemporal control of CRISPR/Cas9 gene editing
    Chenya Zhuo
    Jiabin Zhang
    Jung-Hwan Lee
    Ju Jiao
    Du Cheng
    Li Liu
    Hae-Won Kim
    Yu Tao
    Mingqiang Li
    Signal Transduction and Targeted Therapy, 6
  • [25] The dawn of the CRISPR/Cas9 gene therapy era
    不详
    LANCET HAEMATOLOGY, 2024, 11 (01): : e1 - e1
  • [26] GENE EDITING IN CHONDROCYTES USING CRISPR/CAS9
    Gibson, G.
    Yang, M.
    OSTEOARTHRITIS AND CARTILAGE, 2016, 24 : S2 - S3
  • [27] CRISPR/Cas9: The new era of gene therapy
    Alotaibi, Amal
    INTERNATIONAL JOURNAL OF ADVANCED AND APPLIED SCIENCES, 2020, 7 (10): : 20 - 29
  • [28] Spatiotemporal control of CRISPR/Cas9 gene editing
    Zhuo, Chenya
    Zhang, Jiabin
    Lee, Jung-Hwan
    Jiao, Ju
    Cheng, Du
    Liu, Li
    Kim, Hae-Won
    Tao, Yu
    Li, Mingqiang
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2021, 6 (01)
  • [29] Genome and epigenome editing with CRISPR/Cas9 for gene therapy and disease modeling
    Gersbach, Charles A.
    TRANSGENIC RESEARCH, 2016, 25 (02) : 201 - 201
  • [30] Novel disease resistance gene paralogs created by CRISPR/Cas9 in soy
    Nagy, Ervin D.
    Stevens, Julia L.
    Yu, Neil
    Hubmeier, Chris S.
    LaFaver, Nona
    Gillespie, Megan
    Gardunia, Brian
    Cheng, Qianshun
    Johnson, Steven
    Vaughn, Audrey L.
    Vega-Sanchez, Miguel E.
    Deng, Mingqui
    Rymarquis, Linda
    Lawrence, Richard J.
    Garvey, Graeme S.
    Gaeta, Robert T.
    PLANT CELL REPORTS, 2021, 40 (06) : 1047 - 1058